Showing 2311-2320 of 2652 results for "".
- Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Studyhttps://modernod.com/news/gemini-therapeutics-announces-gem103-meets-all-endpoints-in-phase-1-clinical-study/2478546/Gemini Therapeutics announced that the phase 1 study of GEM103, the company’s investigational treatment for dry AMD, met all its endpoints. Results demonstrate that in 12 patients receiving a single intravitreal (IVT) injection of GEM103, there were no dose-limiting toxicities or treatment-
- Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Material Recycled Through One By One Recycling Programhttps://modernod.com/news/bausch-lomb-reports-nearly-27-million-united-of-contact-lens-material-recycled-through-one-by-one-recycling-program/2478541/Bausch + Lomb announced that its exclusive ONE by ONE Recycling program has recycled nearly 27 million used contact lenses, top foils and blister packs since launching in November 2016. The program, made possible through a collaboration with TerraCycle, a leader in the collection and repurposing
- CDC Now Says Wearing a Mask Protects the Wearer, Toohttps://modernod.com/news/cdc-now-says-wearing-a-mask-protects-the-wearer-too/2478538/For months it has been clear that wearing a face mask reduces the transmission of COVID-19, because it prevents your respiratory droplets from spreading and potentially infecting other people. Now the Centers for Disease Control has highlighted another benefit of mask-wearing that many hoped or s
- American Academy of Ophthalmology Leads Global Initiative to Address Worldwide Myopia Epidemichttps://modernod.com/news/american-academy-of-ophthalmology-leads-global-initiative-to-address-worldwide-myopia-epidemic/2478535/The number of Americans who are nearsighted has nearly doubled over the last 50 years to about 41.6 percent. This upward trend is evident in nearly every corner of the world, but nowhere near as dramatic as in East and Southeast Asia, where 80 to 90 percent of chi
- Zeiss Introduces Video Laryngoscopehttps://modernod.com/news/zeiss-introduces-video-laryngoscope/2478531/With the outbreak of the COVID-19 crisis earlier this year, the Medical Technology segment of Zeiss focused on he
- What a Republican Senate Will Mean for the Health Care Industryhttps://modernod.com/news/what-a-republican-senate-will-mean-for-the-health-care-industry/2478493/Republicans appear likely to hold on slightly to their Senate majority after Tuesday’s elections, which could have a major impact on what healthcare legislation gets through Congress next year, according to a FierceHealthcare
- Gilead’s Veklury Becomes First Treatment to Receive FDA Approval for COVID-19https://modernod.com/news/gileads-veklury-becomes-first-treatment-to-receive-fda-approval-for-covid-19/2478451/Gilead Sciences said Thursday that Veklury (remdesivir) has been approved by the FDA to treat hospitalized COVID-19 patients aged 12 years and older and weighing at least 40 kg, making it the first drug to gain full clearance in the US for the disease. The antiviral, which works by hindering the
- Volunteers to be Infected With Coronavirus in World’s First ‘Human Challenge’ Trialshttps://modernod.com/news/volunteers-to-be-infected-with-coronavirus-in-worlds-first-human-challenge-trials/2478437/Volunteers in London are to be infected with coronavirus early next year, in the world’s first COVID-19 “human challenge trials,” according to a Financial Times report. The project, first disclosed in the Financial Time
- Tepezza Data From Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)https://modernod.com/news/tepezza-data-from-phase-2-clinical-trial-evaluate-longer-term-responses-in-people-living-with-thyroid-eye-disease-ted/2478415/Horizon Therapeutics announced new long-term follow-up data from the phase 2 clinical trial of Tepezza (teprotumumab-trbw), which showed a sustained response up to 1 year following completion of treatment for Thyroid Eye Disease (TED). These data will be presented as part of the
- Will Kids Get A COVID-19 Vaccine? Pfizer To Expand Trial To Ages 12 And Uphttps://modernod.com/news/will-kids-get-a-covid-19-vaccine-pfizer-to-expand-trial-to-ages-12-and-up/2478411/Pfizer announced Monday that it has received FDA approval to enroll children as young as 12 years old in its COVID-19 vaccine trial. The expansion is aimed at understanding whether the vaccine would be safe and effective for adolescents, according to an NPR